



Financial Results Presentation 1H FY26

4 FEBRUARY 2026

Vitrafy Life Sciences Limited (ASX: VFY)
ACN 622 720 254

vitrafy.com
Strictly Private & Confidential

Important Notice and Disclaimer

This presentation is provided by Vitrafy Life Sciences Limited (ACN 622 720 254) (the Company). Statements in this presentation are made only as at the date of this presentation and the information in this presentation remains subject to change without notice. The information in this presentation is of a general nature and does not purport to be complete, is provided solely for information purposes of giving you summary information and background about the Company and its activities, current as at 4 February 2026, and should not be relied upon by the recipient.

This presentation is not, and does not constitute, or form any part of, an offer to sell or issue, or the solicitation, invitation or recommendation to purchase any securities.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation.

This presentation does not purport to summarise all information that a recipient should consider when making an investment decision, and should not form the basis of any decision by a recipient.

Recipients should carry out their own investigations and analysis of the Company and verify the accuracy, reliability and completeness of the information contained in this presentation or any other form of communication to which the recipient is permitted access in the course of evaluating an investment in the Company.

No liability

To the maximum extent permitted by law, the Company, or their respective affiliates or related bodies corporate or any of their respective officers, directors, employees, agents and advisers (Related Parties), nor any other person, accepts any responsibility or liability for, and makes no recommendation, representation or warranty concerning, the content of this presentation, the Company, or the Company's securities including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.

Eligible recipients

This presentation is provided to you as an investor to whom an offer document is not required to be given, and no registration, lodgement or other formality is required, in connection with an offer of securities. In accepting this presentation you warrant that you are an investor within the scope of this paragraph and that you accept this presentation on the basis set out in this notice.

This presentation is not, and does not constitute, or form any part of, an offer to sell or the solicitation, invitation or recommendation to purchase any securities in the United States and neither this presentation nor anything contained herein shall form the basis of any contract or commitment. This presentation may not be distributed or released in the United States. Securities may not be offered or sold in the United States unless such securities are registered under the U.S. Securities Act of 1933, as amended (U.S. Securities Act) or in a transaction exempt from, or not subject to, the registration requirements of the U.S. Securities Act and any other applicable securities laws. Each institution or person that reviews this presentation will be deemed to represent that each such institution or person is not in the United States.

The distribution of this presentation may be restricted by law. Persons who come into possession of this presentation should seek advice and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws.

Confidentiality

This presentation is confidential and not for further distribution. It is provided by the Company on the basis that, by accepting this presentation, persons to whom this presentation is given agree to keep the information confidential, not copy the presentation and not to disclose it, in whole or in part, to anyone within their organisation except on a need-to-know basis and subject to these restrictions, or to anyone outside their organisation.

Important Notice and Disclaimer (cont.)

Not financial product advice

Reliance should not be placed on the information or opinions contained in this presentation. This presentation is for informational purposes only and is not financial product or investment advice or a recommendation to acquire the Company's securities and does not take into consideration the investment objectives, financial situation or particular needs of any particular investor. You should make your own assessment of an investment in the Company and should not rely on this presentation. In all cases, you should conduct your own research of the Company and analysis of the financial condition, assets and liabilities, financial position and performance, profits and losses, prospects and business affairs of the Company and its business, and the contents of this presentation. You should seek legal, financial, tax and other advice appropriate to your jurisdiction.

Past performance

Past performance information given in this presentation is given for illustrative purposes only and should not be relied upon as an indication of (and gives no guidance as to) future performance.

Future performance

This presentation contains certain forward-looking statements (including financial forecasts) with respect to the financial condition, operations and business of the Company and certain plans and objectives of the management of the Company. Forward-looking statements can be identified by the use of forward-looking terminology, including, without limitation, the terms "believes", "estimates", "anticipates", "expects", "predicts", "intends", "plans", "goals", "targets", "aims", "outlook", "guidance", "forecasts", "may", "will", "would", "could" or "should" or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts.

Such forward looking statements involve known and unknown risks, uncertainties and other factors which because of their nature may cause the actual results or performance of the Company to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the political and economic environment in which the Company will operate in the future, which may not be reasonable, and are not guarantees or predictions of future performance. No representation is made that any of these statements or forecasts will come to pass or that any forecast result will be achieved, or that there is a reasonable basis for any of these statements or forecasts.

Forward-looking statements speak only as at the date of this presentation and to the full extent permitted by law, the Company and its respective affiliates and related bodies corporate and each of their respective Related Parties and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).

Financial data

All figures in the presentation are Australian dollars (\$) unless stated otherwise. A number of figures, amounts, percentages, estimates, calculations of value and fractions in this presentation are subject to the effect of rounding. Accordingly, the actual calculation of these figures may differ from the figures set out in this presentation.

Financial information

The pro forma financial information provided in this presentation is for illustrative purposes only and does not represent a forecast or expectation as to the Company's future financial condition and/or performance. This document has been prepared at a time where the review of financial information contained in this presentation has not been completed and accordingly, you should only rely on any expectation as to the Company's future financial condition and/or performance that is contained in a prospectus or other offering document which may be issued by the Company in connection with any offer of the Company's securities.

Acknowledgement

Persons who access, receive, review or attend this presentation are required to inform themselves of, and comply with, all of the above restrictions and prohibitions and none of the Company or the Related Parties accepts any liability to any person in relation thereto. This presentation is made to you on the basis that by attending, accessing or receiving or reviewing this presentation, you confirm that you understand and agree to the contents of this important notice and disclaimer and that you are a person to whom this presentation may lawfully be made in accordance with laws applicable to you, including those of the jurisdiction in which you are located.

Today's Presenters



Brent Owens

Managing Director and Chief Executive Officer



Simon Martin

Chief Financial Officer

1H FY26 Outlook Recap

Vitrafy outlined a clear execution plan at the Company's FY25 results presentation.

Market development



Capture global commercial animal reproduction opportunities - **DELIVERED**



Expand paid human health collaborations – **PROGRESSING OPPORTUNITIES**



Complete Phase 2 blood platelets study; progress to commercialisation- **ON TRACK**



Aggressively scale U.S. operations and team development – **U.S. footprint established and outbound marketing launched.**

Technology development



Unregulated product launch H1 FY26 – **DELIVERED**



Medical Device product launch H2 FY26 – **EXPECTED Q1 FY27**



Build supply chain and manufacturing capability and capacity – **ON TRACK**

1H FY26 Continued Delivery on IPO Commitments

Operational Highlights

Market development

- ✔ Strategic **commercial agreement executed** with IMV Technologies
- ✔ **Phase 2 U.S. platelet study commenced**; strong commercial interest emerging
- ✔ **U.S. operations established**; first Guardion device deployed
- ✔ **Pipeline expanded** across blood, cell and gene therapy

Technology development

- ✔ Guardion and LifeChain **delivered on time and on budget**
- ✔ Guardion FDA registration **commenced**.
- ✔ Commercial Guardion **unit builds to support demand** commenced
- ✔ **U.S. manufacturing establishment** underway, targeting 2H FY26

Financial position

\$22.8m

Total cash and liquid assets.

Up to \$0.9m revenue flowing from commercial contract with IMV over the term of the Agreement.

Further **\$1.6m of grant funding** to come over the balance of calendar 2026.

1

Results and Operational Overview

H1 Achievement Summary



Strategic commercial agreement executed with a global leader in animal health and assisted reproductive technologies.



Phase 1 blood platelet trials completed with the U.S. Military generating commercial interest for civilian applications.



Guardion cryopreservation freezer unit arrived in U.S. and to be used for customer demonstrations.



U.S. go-to-market commercialisation footprint expanded with headcount growth and office opening.

Operational Highlights – Animal Health Commercialisation



Strategic commercial agreement executed with a global leader in animal health and assisted reproductive technologies.

Animal Commercialisation Strategy

- Partnership with global leader for the highly concentrated animal reproduction space.
- Develop a combined market offering that aids market adoption and scale.
- Long-term commercial agreement with the potential to deliver revenue to Vitrafy via a partnership model.
- Focus direct-to-market activities on human health.



12-month, revenue generating commercial agreement with IMV Technologies.



With ~50% market share, IMV has a track record of commercialising innovative technology.



Contract term to develop combined, go-to-market product offering




Clear pathway to both immediate and long-term revenue.

Commercialisation Strategy Execution

Operational Highlights – Animal Health Commercialisation



12-month partnership to co-develop a commercial value proposition and go-to-market plan.



1. All existing Vitrafy aquaculture agreements are excluded from the Agreement

Operational Highlights – Blood & Blood Products



Phase 1 blood platelet trials completed with the U.S. Military generating interest for civilian applications.

- Following on from the successful Phase I trials with the U.S. Army Institute of Surgical Research, Phase II studies of blood platelet freezing was commenced during the half.
- Joint development of the statement of works for the testing program with testing commenced – **initial results from phase II studies expected in 2H FY26**
- Vitrafy and the USAISR co-presented the Phase 1 study results at the Association for the Advancement of Blood & Biotherapies (“AABB”) 2025 Annual Meeting in San Diego, USA in late October.
- Significant civilian blood network **commercial interest** generated as a result of U.S. Military work

Upcoming Milestone

2H FY26: Phase II studies initial data results from expanded testing program

Operational Highlights – Product Delivery



Vitrafy delivered its go-to-market Guardion freezer unit.



Major operational milestone achieved with first operational Guardion device delivery.



Hardware and software projects on-time and budget.



Build out of first batch of 4 devices for commercial use completed.



First Guardion device shipped and commissioned in the U.S.



Commenced FDA device registration workstreams.



Device manufacturing to ramp up across 2H FY26.



Guardion (formerly VCU2)

Operational Highlights – U.S. Operational



**U.S. go-to-market
commercialisation
footprint expanded**

- Key sales, marketing and commercial operations people appointments.
- US headquarters in Irvine California provides U.S. team with a venue to conduct in-person demos.
- Guardion freezer unit in market.


Upcoming Milestone

Q3 FY26: Integrated PR, digital and conference campaign program to create brand awareness and generate leads for the Sales team.

2

Vitrafy Ecosystem, Market and Customer Proposition

One Solution, Multiple Go-to-Market Applications



Animal Reproduction


Vitrafy's cryopreservation ecosystem has broad applicability across biological materials.

Global Scale

Critical for food availability

Commercial Agreement in place

Globally, >2,200 collection sites across aquaculture, bovine and porcine.




Blood & Blood Products

Why

Critical & growing **need**
Global Scale


~ 8,000 points (collection, manufacturing, storage and points-of-care) across the blood cryopreservation supply chain that underpin blood and cell & gene therapy products.



Cell & Gene Therapies

Rapid **growth**
Needs solutions
Global Scale

Vitrafy cryopreservation ecosystem delivers customer value at the solution level.



Vitrafy cryopreservation ecosystem delivers customer value at the solution level.

Legacy cryopreservation technology:

- **Isolated Technology:** Stand alone cryopreservation unit is the current standard.
- **No intelligence or insight:** Data capture and analytics to support GMP compliance and FDA approvals uncommon.
- **Damaging:** use of liquid nitrogen and harmful toxins mandatory throughout process.
- **Expensive:** hidden costs and impacts on the sample costing users time, quality and money.



Guardion Cryopreservation Freezer Unit




LifeChain Software Orchestration Platform

vitrafy
LIFE SCIENCES

Vitrafy Thawing Units



Vitrafy Smart Consumables



The Vitrafy cryopreservation ecosystem:

- **Connected:** end-to-end ecosystem connection.
- **Intelligent:** Data capture and analytics empowering intelligent decision making.
- **Quality:** every step designed to preserve medical grade quality and hygiene.
- **Value Generative:** hidden savings and improved performance, saving time, improving quality and providing a better post thaw product – ultimately, preserving life.

Product – Guardion Value Proposition

Legacy Hardware

- ▼ Manual, operator dependent
- ▼ Limited intelligence
- ▼ Limited throughput
- ▼ Slow and inconsistent freeze cycles (hours)
- ▼ Energy Inefficient
- ▼ Use of unsafe materials such as liquid nitrogen (LN2)
- ▼ Limited portability



Vitrafy Guardion

- ✔ Controlled & tailored cryopreservation
- ✔ Automated & Intelligence
- ✔ Continuous Throughput
- ✔ Rapid processing times <5 min
- ✔ Low Power requirement
- ✔ Liquid Nitrogen Free
- ✔ Integration with LifeChain™

Controlled | Intelligent | LN2 Free

Product – LifeChain Value Proposition


LifeChain delivers quality control across the pre-clinical, clinical and commercial supply chain to support GMP compliance and FDA submission data sets.

Standardisation: Facilitates the standardisation of quality outcomes ensuring consistency across multiple sites.

Auditability: Chain of command functionality ensures workflows are traceable.


Digitisation: Digitising paper workflows to create a single, central source of truth.

Connectivity: IoT connectivity allowing third-party device outcomes to be monitored via the ecosystem.



The screenshot shows the 'Workflows' section of the LifeChain interface. It displays a table with columns for Name, Current Activity, Progress, Assignee, Updated, and Duration. The table lists 11 items, all with a progress of 0% and assigned to Andrew Wyan. The current activity for all items is '1. DONOR COLLECTION FORM'. The updated time for all items is '2 hours ago', and the duration is '2 hours, 21 minutes'.


Name	Current Activity	Progress	Assignee	Updated	Duration
#1002 Sample	1. DONOR COLLECTION FORM	0%	Andrew Wyan	2 hours ago	2 hours, 21 minutes
#1003 Sample	1. DONOR COLLECTION FORM	0%	Andrew Wyan	2 hours ago	2 hours, 21 minutes
#1004 Sample	1. DONOR COLLECTION FORM	0%	Andrew Wyan	2 hours ago	2 hours, 21 minutes
#1005 Sample	1. DONOR COLLECTION FORM	0%	Andrew Wyan	2 hours ago	2 hours, 21 minutes
#1006 Sample	1. DONOR COLLECTION FORM	0%	Andrew Wyan	2 hours ago	2 hours, 21 minutes
#1007 Sample	1. DONOR COLLECTION FORM	0%	Andrew Wyan	2 hours ago	2 hours, 21 minutes
#1008 Sample	1. DONOR COLLECTION FORM	0%	Andrew Wyan	2 hours ago	2 hours, 21 minutes
#1009 Sample	1. DONOR COLLECTION FORM	0%	Andrew Wyan	2 hours ago	2 hours, 21 minutes
#1010 Sample	1. DONOR COLLECTION FORM	0%	Andrew Wyan	2 hours ago	2 hours, 21 minutes
#1011 Sample	1. DONOR COLLECTION FORM	0%	Andrew Wyan	2 hours ago	2 hours, 21 minutes



The screenshot shows the configuration page for a specific workflow activity, '2.2 Transfer Sample into Packaging'. The page includes a sidebar with a tree view of activities and a main form area. The form has a dropdown for 'Select Bag Type' set to 'Cryobags 350', a 'Part Code' field with 'CS210', and several input fields for dimensions and volumes: Width (mm) 12.7, Length (mm) 17.7, Min Volume (ml) 30, and Max Volume (ml) 70.


3

Commercialisation



Value creation


Across FY26, Vitrafy has a clear, milestone-driven roadmap to unlock and accelerate commercial adoption across unregulated and regulated markets



Commercialisation Approach Reminder




Vitrafy has adopted a staged pipeline to progress its innovative technology with partners to the point of commercialisation.



Commercialisation – Business Model

Managed service model supporting LifeChain and customer education captures value beyond individual units.



For a **recurring monthly fee**, users get access to the Vitrafy ecosystem:


- Hardware
- Software
- Support

With the Vitrafy, committed to helping their customers realise **quality, cryopreservation outcomes**

Consumable will be sold separately.

Commercialisation – Device Supply

Investing in a small production batch of Guardion freezer units to enable early commercial deployments, in partnership with Planet Innovation.



Device builds underway in line with expected demand

Units to be allocated to near-term commercial opportunities (e.g. IMV)

Build costs in forecasts supporting CY2027 cash runway

Commercialisation – Manufacturing Capability

With our partner, Planet Innovation, Vitrafy is investing in an outsourced, commercial manufacturing capability to deliver supply of the Guardion device

- U.S manufacturing line currently being established.
 - Cost reduction benefits associated with in-country manufacturing.
 - Economies of scale and sub-assembly to realise further savings.

Upcoming Milestone

Q4 FY26: Establishment of U.S. manufacturing capability

4

Financial Results 1H FY26

Consolidated Statement of Profit & Loss

Summary	31 December 2025	31 December 2024
Sales revenue	8,868	7,704
Other income	1,975,542	680,000
Total income	1,984,410	687,704
Product management	(5,053,798)	(2,383,908)
Sales & marketing	(767,770)	(84,910)
Operations	(1,302,801)	(847,156)
General & administration	(2,366,909)	(4,190,088)
Loss before financing and income tax expense	(7,506,868)	(6,818,358)
Interest income	392,447	49,805
Finance costs	(10,046)	(6,481,057)
Fair value (lost) on embedded derivative	-	(12,433,898)
Loss after income tax expense	(7,124,467)	(25,683,508)
Other comprehensive losses for the half	(94,973)	-
Total comprehensive loss for the half	(7,219,440)	(25,683,508)

Commentary:

- **Sales revenue**, driven by expansion of Huon fertilisation program.
- **~\$1.9m IGP grant earned**, \$1.9m recorded as revenue associated with Industry Growth Program Grant. Cash received during the period of \$750k (plus GST)
- **R&D tax incentive**, extra R&D grant revenue of ~\$38k from FY25. No R&D expected to be claimed in FY26.
- **Product Management**, consultancy and employee costs of the Guardion device and LifeChain developments. Current approach is to expense all development spend – this will be reviewed as customers come on line in current half
- **Sales & Marketing**, growth reflecting the establishment of U.S. operations and sales function

Consolidated Statement of Financial Position

Summary	31 December 2025	30 June 2025
Cash and term deposits	22,798,717	29,595,467
Receivables & prepayments	355,875	672,632
R&D receivable	-	982,639
Current assets	23,154,592	31,250,738
Non-current assets	527,28	593,327
Payables & accrued expenses	1,109,628	774,949
Deferred income	239,071	1,427,668
Lease liability	93,566	89,784
Employee Benefits	276,317	431,723
Current liabilities	1,718,582	2,724,124
Non-current liabilities	312,793	352,129
Net assets	21,650,425	28,767,812
Issued capital	89,685,360	89,685,360
Reserves	2,457,826	2,450,746
Accumulated losses	(70,492,761)	(63,368,294)
Equity	21,650,425	28,767,812

Commentary:

- **\$22.8m cash and liquid assets** on hand, including \$10.1m in term deposits.
- **Cash runway forecast through to CY2027** with elevated expenditure in 2H FY26.
- **Deferred Income** reflects the movement in grant revenue earned during the period net of the grant received during the 1H of \$750k

Cash Flow


Summary	31 December 2025	30 December 2024
Receipts from customers and other income	57,553	41,163
Payments to suppliers and employees	(9,185,153)	(6,122,800)
Net interest received	625,466	37,502
R&D tax incentive received	1,021,529	2,022,825
Government grant received	821,341	-
Operating cash flow	(6,659,264)	(4,021,310)
Investments in term deposits	(10,000,000)	(20,000,000)
Payments for property, plant and equipment	-	(1,854)
Proceeds from disposal of property, plant and equipment	1,381	-
Proceeds from term deposits	10,000,000	-
Investing cash flow	1,381	(20,001,854)
Proceeds from issue of shares	-	35,000,002
Share issue transaction costs	-	(3,215,683)
Exercise of options	-	317,308
Repayment of lease liabilities	(43,894)	(40,343)
Financing cash flow	(43,894)	32,061,284
Net cash flow		
Closing cash	12,723,717	14,450,782
Term deposits	10,075,000	20,075,000
Cash & Liquid Assets*	22,798,717	34,525,782

Commentary:

- **Receipts from customers** relates to the aquaculture work completed as part of the May 2025 cryopreservation process conducted in Tasmania
- **Supplier & Employee payments** increased driven by the Product Development project costs, U.S. operational establishment and general overhead expansion

5

Outlook




Outlook

Vitrafy remains focussed on executing commercialisation agreements in our target market of North America and with our partner in the animal reproduction application, IMV Technologies.

- **The Company will be focussed on:**

- Expand and converting new & existing customer pipeline opportunities in Human Health;
- Successfully complete the phase II studies with the USAISR;
- Commencing work under the agreement with IMV Technologies and scaling existing aquaculture clients;
- Commencing and Securing medical device registration to expand the addressable market in the U.S.
- Building manufacturing capacity in the US and a supply of devices in advance of market demand.

Appendix



Market – Blood Platelets Use Case

Vitrafy's cryopreservation ecosystem proposition is specifically designed to rectify real world problems and realise value for users of the ecosystem.

The need:

Blood platelets play a vital role in stopping bleeding and with high quality, available supply to platelets essential in life-saving trauma situations.

Legacy cryopreservation technology:

Poor Patient Outcomes

Lack of supply and quality of blood products resulting in poor patient outcomes – **90% of preventable deaths** in trauma settings result from haemorrhage.

- **Short Shelf Life** : shelf life limited to 5-7 days post collection.
- **Poor Quality**: 20%-30% of blood platelet quality deteriorates post collection, pre-patient transfusion.
- **Transfusion Risks**: fresh blood products at risk of developing bacteria – increasing the risk to patients of blood transfusion transmitted infections.
- **Critical Shortages**: inability to effectively bio-bank supply, resulting in critical shortages.

The Vitrafy cryopreservation ecosystem:

vitrafy
LIFE SCIENCES


- **Extended Shelf**: shelf life extended via effective cryopreservation freezing and thawing enabling long-term storage.
- **High-Quality**: consistent post thaw recovery and functionality resulting high-quality blood products for transfusion.
- **Limited Transfusion Risks**: point of collection cryopreservation retaining biological materials in steady-state, reducing the need for pathogen reduction additives and limiting risk of transfusion-based infection.
- **Inventory Flexibility**: ability to effectively bio-bank blood products mitigating demand and supply impacts on the provision of critical care.

High Quality Patient Outcomes

Market – Blood Platelets Use Case


The USAISR phase 1 study not only exceeded all regulatory and industry standards but highlighted the game-changing market opportunity.

Problem Current industry standards



Poor Patient Outcomes

Vitrafy solution Game changing outcomes



High Quality Patient Outcomes

Market – Cell and Gene

ClinicalTrials Arena

News Analysis Sectors Themes Insights Companies Webinar & Events Buy Reports Newsletters

News

FDA increases manufacturing flexibility for cell and gene therapies

Clinical and commercial quality controls are eased as the FDA looks to expedite therapy approvals in areas of unmet need.

Frankie Fattorini | January 12, 2025

Technology Networks

Cell Science

Science News Communities

Home > Cell Science > Listicles > Content Piece

Cell Therapies on Ice: Seven Trends in Cryopreservation To Enable Cell and Gene Therapy Research

BioProcess International

Upstream Downstream Manufacturing Analytical Business Therapeutic Modalities

MEMBERS ONLY CELL THERAPIES

Unlocking Regenerative Medicine Through Cell Cryopreservation

The need:

Patient recovery time is required between cell collection and treatment due to the extraction burden.

Legacy cryopreservation technology:

Inherent consistency and scalability limitations undermine reliable cell and gene manufacturing.

- **Operator-dependent variability** undermines batch-to-batch consistency required for GMP manufacturing.

- **Minimal data capture** limits traceability and the generation of robust datasets to support regulatory submissions.

- **Lower post-thaw viability** increases batch failure risk and complicates GMP release criteria.

- **Poor scalability** from research protocols to a clear, consistent GMP manufacturing pathway

vitrafy

LIFE SCIENCES

- **Standardised, automated processes** that improve batch-to-batch consistency for GMP manufacturing.

- **End-to-end data capture and traceability** to generate robust datasets that support regulatory submissions.

- **Improved post-thaw viability** to reduce batch failure risk and simplify GMP release criteria.

- **A scalable pathway** from research through to clinical and commercial GMP manufacturing.

- **Optimised efficiency and transparency** across the freeze–store–thaw lifecycle, reducing waste and accelerating delivery

High Quality Patient Outcomes